CareLit · DOI-Nachweis · Pneumologie
CheckMate 817: Safety of flat-dose nivolumab (nivo) plus weight-based ipilimumab (ipi) for the first lie (1 L) treatment of advanced non-small cell lung cancer (NSCLC)
DOI 10.1055/s-0039-1678251
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJR Fischer, L Paz-Ares, L Urban, C Audigier-Valette, F Grossi, K Jao, JS Aucoin, H Linardou, E Vladimirovna Poddubskaya, A Cuiioni Fontecedro, HJM Groen, K Vermaelen, M Bourhaba, D Kowalski, R Narayana Pillai, DR Spigel, S Ahmed, W Hu, D Vickery, J Fiore, N Ready
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
CheckMate 817: Safety of flat-dose nivolumab (nivo) plus weight-based ipilimumab (ipi) for the first lie (1 L) treatment of advanced non-small cell lung cancer (NSCLC)
Zitieren
Zitierempfehlung
JR Fischer, L Paz-Ares, L Urban, C Audigier-Valette, F Grossi, K Jao, JS Aucoin, H Linardou, E Vladimirovna Poddubskaya, A Cuiioni Fontecedro, HJM Groen, K Vermaelen, M Bourhaba, D Kowalski, R Narayana Pillai, DR Spigel, S Ahmed, W Hu, D Vickery, J Fiore, N R… (2019) CheckMate 817: Safety of flat-dose nivolumab (nivo) plus weight-based ipilimumab (ipi) for the first lie (1 L) treatment of advanced non-small cell lung cancer (NSCLC). Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678251
Mit CareLit weiterarbeiten